Loading…
Loading…
Pacific Biosciences of California (PACB) closed at $1.27 in the latest trading session, marking a -1.55% move from the prior day.
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock?
MENLO PARK, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 4:50 PM ET in New York, New York.
PacBio cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition raised the stakes for clinical adoption.
On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.
Pacific Biosciences of California NASDAQ: PACB reported second-quarter revenue of $39 million, including $20 million in consumables revenue, $13 million in instrument revenue and $6 million in services revenue, CFO Jim Gibson said during the Canaccord Genuity Growth Conference.
PACB cuts its 2026 revenue outlook after Q2 sales fall 2%, as consumables and EMEA growth fail to offset weaker instruments and Asia-Pacific.
Pacific Biosciences reported Q2 revenues of $39.01 million, missing estimates and guiding 2026 revenues down, below consensus. Operating and net losses remain sizable, with cash now under $237 million and nearly $645 million in debt outstanding. PACB trades at 2.4x expected 2026 revenues, a steep discount to peers, reflecting weaker financials and growth prospects.